

**PRESSURE BIOSCIENCES INC.**

14 Norfolk Avenue  
South Easton, MA 02375  
(T) 508-230-1828  
(F) 508-230-1829  
[info@pressurebiosciences.com](mailto:info@pressurebiosciences.com)

Mr. Richard T. Schumacher, CEO, President  
Dr. Edmund Y. Ting, SVP of Engineering  
Dr. Nathan P. Lawrence, Vice President of M&S  
Dr. Alexander V. Lazarev, Vice President of R&D

---

**STOCK OVERVIEW**

Symbol:	PBIO	Recent Bid:	\$0.22 (as of 2/24/17)
Exchange:	OTCQB	52-Week Range:	\$0.15 - \$0.58
Shares OS <sup>1</sup> :	75M (Fully Diluted)	Market Capitalization <sup>2</sup> :	\$16.5M
Float:	~25M	Fiscal Year End:	December 31
Revenue (9 Mo 2016):	\$1.55M	Transfer Agent:	Computershare

---

**COMPANY OVERVIEW**

**Pressure BioSciences, Inc. ("PBI")** is a life sciences tools company focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on our game-changing Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels (up to 90,000 psi or greater) to safely, conveniently and reproducibly control the actions of molecules (i.e., inactivate, break (lyse), liberate, extract, and/or prepare for downstream analysis) from biological samples, such as cells and tissues from human, animal, plant, and microbial sources. We currently focus the majority of our efforts on the development and sale of PCT systems (instruments and consumables) to address the challenging problems inherent in biological sample preparation, a crucial laboratory step performed by thousands of scientists worldwide working in biological life sciences research.

Sample preparation is a term that refers to a wide range of activities that precede most forms of scientific analysis. Sample preparation is often complex, time-consuming, and one of the most error-prone (but crucial) steps of scientific research. It is a widely-used laboratory undertaking, the requirements of which drive a large and growing market, estimated currently at approximately \$6 billion worldwide. PBI's PCT systems can be used to exquisitely control the sample preparation process. PCT uses internally developed instrumentation that is capable of cycling pressure between ambient and ultra-high levels, at specific temperatures and time intervals, to rapidly and repeatedly control the interactions of bio-molecules, such as DNA, RNA, proteins, lipids, metabolites, and other small molecules. Our product line includes five different models of pressure-generating instruments and over a dozen different consumables. Together the instruments and consumables make up our PCT Sample Preparation System, or PCT Platform.

Our website contains over 100 publications – many from world-renowned scientists, addressing key attributes and advantages of PCT. These advantages include: (a) extraction and recovery of more integral, membrane-bound proteins versus competitive methods (approximately 80% of all new biological drugs in development are directed against such proteins); (b) significantly enhanced proteolysis (digestion of proteins); (c) differential lysis (breakage) of targeted cell types in a mixed sample base (i.e., female skin cells vs. male sperm heads in a rape kit swab sample); (d) ability to fully inactivate dangerous pathogens, such as anthrax; (e) increased detection of DNA and proteins in forensic, infectious disease, cancer, cardiac, neonatal, and other sample types; and (f) the ability to exquisitely control and standardize the sample preparation process.

Through September 30, 2016, PBI has sold or leased over 275 PCT Sample Preparation Systems to approximately 175 leading academic, government, biotech, and pharmaceutical companies. Current customers use the PCT Platform for a wide assortment of important applications, including sample preparation for biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.

---

1. Shares Outstanding (as of December 31, 2016) – includes approximately 31M common shares, 20M common share equivalents from Preferred Stock Series D, G, H, J, and K on an as-converted basis, and 24M 2015 PIPE Debentures.  
2. Market Capitalization is calculated using Common and Common Equivalent Shares OS on a Fully Diluted basis.

## INVESTMENT HIGHLIGHTS

- Seasoned Management Team & Board of Directors
- Novel, Enabling, Patent Protected, Proprietary Platform (PCT)
- Proven Core Technology with Multiple Applications (over 275 PCT systems placed)
- Razor/Razorblade Business Model
- Sales into the Research Market (fast market penetration with minimal approvals required)
- Increasing Number of 3rd Party Publications from Marquee Laboratories
- PCT Breaks Through Bottlenecks and Barriers to Enable and Accelerate Scientific Discovery
- PCT Exquisitely Controls Test Variables, Providing Methods Standardization/Reproducibility
- Significant Market Opportunity (~\$6 Billion from ~500K scientists in 80K labs worldwide)

---

## RECENT & KEY ANNOUNCEMENTS

- **February 2, 2017**, the Company announced it had met the requirements of the EU's *in vitro* diagnostic directive and will immediately begin to apply the CE Mark on its recently released, next-generation Barocycler 2320EXTREME sample preparation instrument.
- **November 16, 2016**, the Company announced its third consecutive quarter with revenue over \$500K; Products and Services revenue sets record highs for a quarter and nine-month period to date.
- **November 14**, PBI announced the initial close of \$610K in a \$2.5 million PIPE, priced at a premium to market
- **November 3**, PBI announced the Close of a \$2,000,000 Line-of-Credit on favorable terms to shareholders
- **October 26**, PBI reported that its PCT platform was featured at the official launch of a major cancer research center (ProCan – Sydney, AU); ProCan is an official collaborator to the NCI in the NIH's "Cancer Moonshot".
- **August 16**, the Company reported back-to-back \$500,000 revenue quarters (Q1 and Q2 2016), a 42% increase in product revenue for Q2 2016 vs. Q2 2015, and record consumable sales for Q2 2016 and 1H 2016.
- **July 21**, PBI announced the initial shipment of its Barocycler 2320EXTREME to an Australian cancer research group (ProCan) named by the White House as a collaborator in the US's "Cancer Moonshot" initiative.
- **July 13**, Barocycler 2320EXT unveiled at the June 2016 ASMS Annual Meeting. The Company expects this next generation PCT-based instrument to be the centerpiece of its co-marketing program with global analytical technologies leader SCIEX. The Company also announced that scientists from six separate research groups made presentations at the conference on the compelling advantages of PBI's patented PCT platform.
- **May 18**, PBI announced Q1 2016 financial results, including a 16% increase in total revenue and a 26% increase in products and services revenue.
- **April 12**, PBI announced it had been added to the high-performing Richmond Club Index
- **April 7**, PBI announced the close of its \$5M PIPE at an over-subscribed amount of \$6.3M. All five of the Company's Board of Directors participated in the final tranche of the PIPE. The Company also announced that 100% of its floorless debt had been eliminated, without any lender converting its loans into Company shares.
- **April 6**, PBI reported 2015 revenue of approximately \$1.8M compared to 2014 revenue of approximately \$1.37 M, an increase of about 31%. Product sales and grant revenue also increased in FY 2015 vs. FY 2014.
- **January 28**, Emerging Growth LLC states in a published article that the combination of PBI's and SCIEX's technologies could result in superior biological insights and discoveries and in rapid and dramatic revenue growth for PBI.
- **January 12, 2016**, SCIEX, a global leader in life science analytical technologies, and a wholly-owned subsidiary of Danaher Corporation (NYSE: DHR), announces an exclusive co-marketing agreement with PBI to improve protein quantitation in complex samples
- **October 16, 2015** the Company announced a collaboration agreement with Florida International University to co-develop an improved rape kit test method, based on the Company's patented PCT platform. With a backlog of untested rape kits estimated at approximately 400,000, an improved testing method is vitally needed.
- **September 1**, the Company announced that a recent publication in a peer-reviewed journal indicated that PBI's PCT platform could play a significant role in personalized/precision medicine, including cancer tissue biopsies.
- **July 15**, the Company announced that PCT was a key workflow component in a study to discover potential biomarkers and underlying pathways in the emergence and progression of COPD-associated lung cancer.
- **July 13**, PBI reported that Chinese and Swiss researchers suggested a workflow that included the PCT platform that they believed could potentially accelerate the discovery of new biomarkers for the early diagnosis and prediction of complications in diabetes.
- **July 7**, the Company announced promising results when its PCT Platform was incorporated in a new method for improving the extraction of DNA from rape kits and other forensic samples.
- **June 29**, the Company announced that scientists from the Institute of Molecular Systems Biology in Zurich, Switzerland presented data on an improved method for the proteomic profiling and classification of prostate cancer tissue biopsy samples at an important international scientific conference.
- **February 19, 2015** the Company announced the award of a \$1 million NIH SBIR Phase II Grant to develop a high-throughput, high pressure-based DNA Shearing System for Next Generation Sequencing ("NGS").

---

## BOARD OF DIRECTORS

- Mr. Jeffrey N. Peterson, Chairman
- Mr. Kevin A. Pollack, Esq.
- Mr. Vito Mangiardi
- Dr. Mickey Urdea
- Mr. Richard T. Schumacher

2/24/17